May 4, 2018 10:40 AM EDT

Regeneron ditches higher dose of pain drug fasinumab in PhIII, triggering safety scare; In a small win for Alnylam, FDA delays review for Ionis' inotersen

Brittany Meiling

→ Regeneron $REGN has canned its high dose arm of fasinumab, an osteoarthritis and back pain drug being tested in Phase III trials, following recommendations …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron ditches higher dose of pain drug fasinumab in PhIII, triggering safety scare; In a small win for Alnylam, FDA delays review for Ionis' inotersen

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Re­gen­eron ditch­es high­er dose of pain drug fas­inum­ab in PhI­II, trig­ger­ing safe­ty scare; In a small win for Al­ny­lam, FDA de­lays re­view for Ion­is' in­ot­ersen

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Regeneron ditches higher dose of pain drug fasinumab in PhIII, triggering safety scare; In a small win for Alnylam, FDA delays review for Ionis' inotersen

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?